← Leaderboards
Katelyn Arnold
Glycan Therapeutics Corporation
$1,234,308
Attributed
$1,461,808
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $775.7K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,461,808 · 3
By mechanism
R42$775,669 · 1
R41$455,000 · 1
R43$231,139 · 1
Top collaborators
- Vijayakanth Pagadala3 shared
Most similar at Glycan Therapeutics Corporation
Same institution · by research overlap
- Zhangjie Wang$4,365,125
- Vijayakanth Pagadala$12,153,122
Others in their field
Other Emerging Leaders on “Structure”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$68,763,143
- Leonard Freedman · Leidos Biomedical Research, Inc.$67,827,589
- John Damon Chodera · Sloan-Kettering Inst Can Research$62,074,236
Research focus
StructureLiver IschemiaUniversitiesIschemiaExperimental StudyLiver InjuryReperfusion InjurySuccessInflammationHeparinReperfusion TherapyOligosaccharidesCryopreservationLiver Cancer PatientComplicationLiver FunctionLiver NeoplasmsAnticoagulantsCollaborationsAdverse OutcomeHeart ArrestFlushingAnti-Inflammatory AgentsBiliary
Grant awards (5)
Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantation$775,669
R42 · FY2025 · CA · contact PI
National I-Corps: Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantation$55,000
R41 · FY2024 · CA · contact PI
Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation$251,076
R41 · FY2023 · CA · contact PI
Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation$148,924
R41 · FY2023 · CA · contact PI
Development of heparan sulfate-based therapeutics to treat inflammatory diseases$231,139
R43 · FY2021 · GM · contact PI